Keyword: Genfit

Green traffic light

Zydus Cadila | Saroglitazar

Zydus’ saroglitazar is approved in India to treat hypertriglyceridemia—high triglyceride levels—in patients with Type 2 diabetes. In a study presented at this year’s American Association for the Study of Liver Diseases meeting, the company tested three doses of the drug against placebo in patients with nonalcoholic fatty liver disease who were also overweight.

Genfit | Elafibranor

Although Intercept’s OCA is on track to beat elafibranor to market, Genfit is hopeful its candidate could be better. For starters, it has a different mechanism: Elafibranor is a dual agonist of PPAR-alpha and PPAR-delta, a type of protein found inside cells that plays a role in cellular metabolism.